Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02681861
Other study ID # 6294-CL-0001
Secondary ID 2014-003451-59
Status Completed
Phase Phase 1
First received January 21, 2016
Last updated January 9, 2017
Start date January 2016
Est. completion date December 2016

Study information

Verified date January 2017
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending intravenous doses and single subcutaneous (sc) doses of ASP6294 in healthy young male and female subjects.

This study will also evaluate the pharmacokinetics (pk) of single ascending intravenous doses and single ascending sc doses of ASP6294; determine the effect of ASP6294 administered intravenously and sc on the serum levels of circulating total Nerve Growth Factor (NGF); explore a potential gender difference in safety, tolerability and pk of single intravenous dose and single sc doses administrations of ASP6294 as well as determine the maximum tolerated dose (MTD) of single intravenous doses and single sc doses of ASP6294.

Part 2 will also evaluate the relative bioavailability of ASP6294 when administered sc.


Description:

The study consists of two parts: Part 1 (ascending intravenous dose) and Part 2 (ascending subcutaneous dose). Subjects will participate in either Part 1 or Part 2. Subjects in Part 1 and Part 2 will have a residential period of 6 days followed by outpatient visits.


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Subject has a body mass index range of 18.5 - 30.0 kg/m2, inclusive, and the subject weighs at least 50 kg (at screening).

- Female subject must either:

- Be of non-childbearing potential: Post-menopausal (defined as at least 1 year without any menses) prior to screening, or Documented surgically sterile

- Or, if of childbearing potential: Agree not to try to become pregnant during the study and for 120 days after final study drug administration; Must have a negative pregnancy test at screening and day -1; And, if heterosexually active, agree to consistently use 2 forms of birth control starting at screening and throughout the clinical study period and for 120 days after final study drug administration.

- Female subject must agree not to breastfeed starting at screening and throughout the clinical study period, and for 120 days after final study drug administration.

- Female subject must not donate ova starting at screening and throughout the clinical study period, and for 120 days after final study drug administration.

- Male subject and their female spouse/partner who are of childbearing potential must be using a highly effective form of birth control† in combination with a barrier method starting at screening and throughout the clinical study period and for 120 days after final study drug administration.

- Male subject must not donate sperm starting at screening and throughout the clinical study period and for 120 days after final study drug administration.

- Subject agrees not to participate in another interventional study during participation in the present study, defined as signing the informed consent form until completion of the last study visit.

Exclusion Criteria:

- Female subject who has been pregnant within 6 months prior to screening assessment or breast feeding within 3 months prior to screening.

- Subject has a known or suspected hypersensitivity to ASP6294 or any components of the formulation used.

- Subject has been exposed to a biological drug within the last 6 months prior to screening.

- Subject has a history of allergic or anaphylactic reaction to a biological drug.

- Subject has been diagnosed with osteoarthritis (OA) or has a history of rapidly progressive OA.

- Subject has any of the liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma glutamyl transferase, total bilirubin [TBL]) above the upper limit of normal (ULN) at day-1. In such a case, the assessment may be repeated once.

- Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

- Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (including orthostatic hypotension and autonomic neuropathy), dermatologic, psychiatric, renal and/or other major disease or malignancy, as judged by the investigator.

- Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to day -1 (admission day).

- Subject has any clinically significant abnormality following the investigator's review of the physical examination, ECG and protocol-defined clinical laboratory tests at screening or day -1.

- Subject has a mean pulse < 40 or > 90 beats per minute; mean systolic blood pressure > 140 mmHg; mean diastolic blood pressure > 90 mmHg (vital sign measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) at screening and day -1. If the mean blood pressure exceeds the limits above, 1 additional triplicate measurement can be taken.

- Subject has a mean corrected QT interval using Fridericia's formula (QTcF) of > 430 ms for males and > 450 ms for females at screening and day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken (admission day).

- Subject uses any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g. St. John's Wort) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day) or the use of contraceptives or hormone replacement therapy.

- Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.

- Subject has a history of drinking more than 21 units (male subjects) or 14 units (female subjects) of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit or the subject tests positive for alcohol or drugs of abuse at screening or day-1 (amphetamines, barbiturates, benzodiazepines, tetrahydrocannabinoids, cocaine, and opiates).

- Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.

- Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit regularly.

- Subject has experienced significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission to the clinical unit.

- Subject has a positive serology test for hepatitis B surface antigen, hepatitis A virus antibodies (immunoglobulin M), hepatitis C virus antibodies, hepatitis B core antibodies, or antibodies to human immunodeficiency virus types 1 and 2.

- Subject participated in any clinical study or has been treated with any investigational drugs within 3 months prior to screening.

- Subject has any condition which, in the investigator's opinion, makes the subject unsuitable for study participation, such as phobias for intravenous or subcutaneous needles/injections.

- Subject is an employee of the Astellas Group or a contract research organization.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
ASP6294 Intravenous
Intravenous (IV)
ASP6294 Subcutaneous
Subcutaneous (SC)
Placebo Intravenous
Intravenous (IV)
Placebo Subcutaneous
Subcutaneous (SC)

Locations

Country Name City State
United Kingdom Site GB44001 Harrow

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Europe B.V.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of ASP6294 as assessed by Nature, frequency and severity of Adverse Events (AEs) Up to 120 Days No
Primary Safety of ASP6294 as assessed by Vital signs Vital signs include blood pressure, pulse and oral body temperature Up to 120 Days No
Primary Safety of ASP6294 as assessed by Neurological examination Neurological Assessment will be measured on a scale for the following Neurological examinations: Gait; Coordination; Speech; Cranial Nerves; Sensations; Muscle Strength; Muscle Tone; Muscle Movement and Reflexes and will be rated as "Normal" or "Abnormal". Up to 120 Days No
Primary Safety of ASP6294 as assessed by laboratory tests Laboratory tests include hematology, biochemistry and urinalysis Up to 120 Days No
Primary Safety of ASP6294 as assessed by routine 12-lead Electrocardiogram (ECG) Up to 120 Days No
Primary Safety of ASP6294 as assessed by continuous cardiac monitoring (Holter ECG) (part 1 only) ECGs are to be collected using a 12-lead ECG continuous monitoring and recording system. Days 1 and 2 No
Primary Safety of ASP6294 as assessed by Sensory assessments Sensory Assessment will be measured on a scale for Lower Limbs and Hands. The following categories: Touch Pressure; Pinprick; Vibration and Joint Position will be rated as Normal (=0 points), Decreased (= 1 point) or Absent (=2 points). A total score for the left and right side of lower limbs and hands will be calculated. Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: AUClast Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: AUC168h Area under the concentration-time curve from the time of dosing to 168 hours postdose (AUC168h) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: AUCinf Area under the concentration-time curve from the time of dosing extrapolated to time infinity (AUCinf) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: Cmax Maximum concentration (Cmax) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: CL (part 1 only) Total systemic clearance after intravenous dosing (CL) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: CL/F (part 2 only) Apparent total systemic clearance after extravascular dosing (CL/F) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: ?z Terminal elimination rate constant (?z) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: MRT Mean residence time (MRT) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: tmax Time of maximum concentration (tmax) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: t1/2 Terminal elimination half-life (t1/2) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: Vss (part 1 only) Volume of distribution at steady state determined after intravenous dosing (Vss) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: Vz (part 1 only) Volume of distribution during terminal elimination phase after intravenous dosing (Vz) Up to 120 Days No
Secondary Pharmacokinetics of ASP6294: Vz/F (part 2 only) Apparent volume of distribution during the terminal elimination phase after extravascular dosing (Vz/F) Up to 120 Days No
Secondary Pharmacodynamics of ASP6294 Nerve growth factor (NGF) total serum concentration: Cmax Up to 120 Days No
Secondary Pharmacodynamics of ASP6294 NGF total serum concentration: tmax Up to 120 Days No
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1